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cal response to short and long term treatment, based on all available randomized 
controlled trials (and indirect comparisons, where appropriate). All costs, in 2012 
Colombian pesos (1 USD$ = COP$1800) were obtained locally, using official databases 
for drug costs, and tariff manual (ISS 2001+30%) for procedures and complications. 
HAQ scores were used to calculate utilities, measured in QALYs. Annual discount 
rate was 3% both for cost outcomes. Results: Total costs, in million COP$, for the 
first year of treatment were $25.51 for adalimumab, $26.96 for certolizumab, $26.94 
for etanercept, $34.79 for golimumab, $25.63 for infliximab and $22.71 for tofacitinib. 
Tofacitinib represented a 16% cost reduction over a market-share weighted average 
of biological therapy in the first year, with equivalent or slightly better QALY gain 
(0.62 vs. 0.61). Cost savings and utility gained were maintained, and dominance was 
attained in more than 50% of Monte Carlo trials in the different time horizons and 
against all comparators considered. ConClusions: Under our model assumptions, 
and current costs in Colombia, for the national health care system, the sequence 
initiating with tofacitinib is a cost-saving alternative compared with biological 
therapy after failure to methotrexate in adults with rheumatoid arthritis, attaining 
at least the same average effectiveness in all the different time horizons considered.
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objeCtives: Rheumatoid Arthritis (RA) can be treated with TNFα inhibitors after the 
failure of conventional disease-modifying antirheumatic drugs like methotrexate. The 
percentage of German patients treated with TNFα inhibitors has been rising from 2 
% in 2000 to 20 % in 2008. In 2012, adalimumab was the most popular TNFα inhibitor 
and the best selling drug in the German statutory health insurance system with net 
expenditure of 581 mn € . We aim to analyze the cost-effectiveness of adalimumab for 
the treatment of RA in Germany. Methods: We set up a Markov Chain Monte Carlo 
lifetime model to simulate 10,000 hypothetical patients. Initially, patients can achieve 
one of three responses according to American College of Rheumatology criteria or 
fail the therapy. Each response is associated with an initial improvement in func-
tional status. In each cycle, treatment might be discontinued due to loss of efficacy 
or adverse events. Results: In the base case, patients gain 2.64 quality-adjusted 
life years (QALYs) with methotrexate monotherapy and 6.25 QALYs if adalimumab 
combination therapy is added to the treatment algorithm. The incremental cost-utility 
ratio (ICUR) is 32,210 € based on German list prices. After deduction of mandatory 
rebates and taxes, the ICUR is only 23,755 € . Adalimumab combination therapy low-
ers indirect cost from 295,070 € to 235,531 € . The ICUR based on total cost is 15,728 € 
(7,274 € after deducting taxes and rebates). ICURs further improve for younger baseline 
age. Limiting the simulation time to 5 or 10 years increases ICURs. ConClusions: 
Adalimumab therapy for the treatment of RA is cost-effective in Germany even in the 
base case scenario, which uses incorrectly high list prices and ignores indirect cost 
savings. Our analysis shows that cost-effectiveness analysis of drugs for chronic dis-
eases need to consider indirect costs and need to take a lifetime modeling perspective.
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objeCtives: Osteoarthritis commonly co-occurs with depression leading to poor 
health outcomes and high economic burden. The objective was to examine the con-
tributing factors to excess total health care expenditures associated with depres-
sion among those with osteoarthritis using a post-regression linear decomposition 
approach. Methods: Data were derived from the 2010 Medical Expenditure Panel 
Survey (MEPS) and self-reported osteoarthritis and depression were identified. Chi-
square tests and ordinary least square regressions (OLS) on log-transformed expen-
ditures were used to determine the association between depression status and 
health care expenditures after controlling for predisposing (gender, race, and age), 
enabling (marital status, education, employment, poverty status, insurance cover-
age, and usual source of care), need (perceived physical and mental health, anxi-
ety, presence of cardiovascular conditions, and other chronic conditions), lifestyle 
(Body-Mass index, exercise, and smoking status), and external environment factors 
(metro versus non-metro). Post-regression linear decomposition technique was used 
to estimate the relative contribution of individual-level variables to the excess expen-
ditures associated with depression and osteoarthritis compared to those without 
depression. Results: Among individuals with osteoarthritis 20.6% reported having 
depression. The average total health care expenditures were $13,684 for those with 
depression compared to $9,284 among those without depression. OLS regression on 
log-transformed total health care expenditures revealed that those with depression 
had 38.8% greater health care expenditures (p < 0.001) compared to adults without 
depression. Post-regression linear decomposition analysis indicated that nearly 50% 
of the difference in average health care expenditures among adults with and without 
depression can be explained by differences in individual-level characteristics between 
the two groups. These differences may be attributable mainly to the need factors 
such as perceived health status, anxiety, presence of cardiovascular conditions, and 
other chronic conditions. ConClusions: Results from the study suggest that excess 
health care expenditures associated with depression may be reduced by improving 
the co-management of chronic physical and mental health conditions.
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fracture incidence. For example, the published incidence_pop for spinal fractures 
for males age 80-84 is reported as 3.58/1,000 patient-years. When incidence_pop is 
used as incidence_no_risk, our model predicted 6.89 spinal fractures/1,000 patient-
years. After adjustment, the model predicted the fracture incidence accurately 
as 3.45/1,000 patient-years. ConClusions: The fracture incidence in non-risk 
patients, the baseline incidence used in the model, can be calculated using this 
method based on the fracture incidence from the study population, the risk factor 
prevalence, and the relative risk increase associated with the risk factor.
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objeCtives: Many patients with rheumatoid arthritis (RA) fail to respond ade-
quately to first-line therapy with conventional disease-modifying antirheumatic 
drugs (cDMARDs). Biologic disease-modifying antirheumatic drugs (bDMARDs) 
have improved outcomes, and multiple guidelines National Institute for Health 
and Care Excellence (NICE) govern their prescription in England and Wales. The 
study objective was to estimate the cost-effectiveness of treatment sequences of 
alternative bDMARDs versus cDMARDs in patients who have failed to respond to 
at least two cDMARDs. Methods: A discrete event simulation model was used 
to explore the cost-effectiveness of bDMARDs in combination with methotrexate 
versus cDMARDs. Populations of interest were patients with severe and moderate 
to severe RA who failed to respond to at least two cDMARDs including methotrex-
ate (cDMARD-IR). In the severe population, eight alternative bDMARD strategies 
and one cDMARD strategy were considered. In the moderate population, a single 
bDMARD strategy was compared against a cDMARD strategy. Strategies evaluated 
differed by the therapy with which the strategy began (a bDMARD or cDMARDs) 
and thereafter were based on current NICE guidance. The perspective was that of 
the UK National Health Service and Personal Social Services. The main outcome 
was the incremental cost-effectiveness ratio (ICER, expressed as cost per quality-
adjusted life years). Results: In a severe population, etanercept resulted in an 
ICER of £20,520 versus a cDMARD strategy (7 strategies strictly or extendedly domi-
nated). In a moderate to severe population the ICER for the etanercept strategy 
was £24,727 versus the cDMARD strategy. In probabilistic sensitivity analysis, the 
etanercept strategy had the highest probability of being cost-effective at a thresh-
old of £30,000. ConClusions: Based on the results of this analysis, a treatment 
strategy beginning with etanercept was considered to be the most cost-effective in 
patients with severe and moderate to severe RA who failed to respond to at least 
two conventional DMARDs.
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objeCtives: Following a recent price regulation for biopharmaceutical products 
in Colombia, we aimed to determine the impact on the cost of treatment with bio-
logic therapies for rheumatoid arthritis in patients who failed to respond to oral 
DMARDS. Methods: Current guidelines and evidence suggest similar efficacy and 
safety among 7 biologic products available in Colombia for the treatment of rheu-
matoid arthritis following DMARD failure: abatacept, adalimumab, certolizumab, 
etanercept, golimumab, infliximab and tocilizumab. We compared the annual direct 
medical cost of treatment (including drug costs, administration and monitoring) 
for intravenous (IV) and subcutaneous (SC) injections of these biologics. Dosages 
were determined based on the approved product labels and the average weight (62 
Kg) for a cohort of 275 patients with rheumatoid arthritis from a private institu-
tion in Bogota, Colombia. Costs were calculated using the data from most current 
price regulation guidance from the Ministry of Health (Circular 04-05/2013) and 
official sources for payments of treatments and procedures (SISMED). Sensitivity 
analyses were performed using different dosages and patients’ weights. Results: 
Direct annual cost of treatment with biologics was higher in the first year than in 
subsequent years, except for tocilizumab, etarnercept, adalimumab and golimumab 
which do not need additional dosages in the first year. Abatacept, both IV and SC, 
consistently showed the lowest direct medical cost after 3 years. The additional cost 
of treatment with other biologic therapies compared to abatacept ranged from 11% 
to 48% after 3 years. Despite having additional costs of administration, IV biologics 
had lower total direct medical cost compared to SC, mainly due to higher cost per 
dosage of the drugs. ConClusions: Under the current price regulation for biolog-
ics in Colombia, the cost of treatment for rheumatoid arthritis favors the use of 
abatacept as a first line biologic after DMARD failure.
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objeCtives: To compare, from the Colombian health care system perspective, both 
costs and effectiveness of tofacitinib with biological therapy as initial treatment in 
adults with rheumatoid arthritis after failure to methotrexate. Methods: We used 
an Excel-based patient level simulation model to compare, with different time hori-
zons (1, 2, 3 , 5, 10, and 20 years), cohorts of patients with tofacitinib as initial therapy 
compared with adalimumab, certolizumab, etanercept, golimumab or infliximab. 
All the patients modeled received concomitant treatment with methotrexate. The 
characteristics of the patients included: age, weight, initial HAQ score, and clini-
